Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00008853|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : August 27, 2010
The purpose of this study is to test the safety and favorable immune response to an anti-streptococcal vaccine (a vaccine that treats a common bacterial infection) in healthy non-pregnant women.
Group B Streptococcus (GBS) continues to be the single most frequent cause of life-threatening bacterial infection during the first 2 months of life. Further, GBS pregnancy-related morbidity afflicts more than 50,000 women annually in the US. Therefore, active immunization of women is an appealing strategy for the prevention of GBS disease in pregnant women and their infants during the first 3 months of infant life.
|Condition or disease||Intervention/treatment||Phase|
|Bacterial Infections Group B Streptococcus||Biological: GBS III-TT-SSI Biological: GBS III-TT-MPHL||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||65 participants|
|Official Title:||Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines|
|Study Completion Date :||November 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00008853
|United States, New York|
|New York, New York, United States, 10011|